Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
Innovate UK (part of UKRI) opened the Growth Catalyst - Investor Partnerships Round 2 competition on 10 December 2025, allocating a minimum of £100 million in grant funding to UK-registered SMEs at seed-to-Series-A stage. Grants (60-70% of project costs for feasibility and industrial-research projects; 35-45% for experimental development) must be matched by private investment from an Innovate UK-approved investor partner, ranging from an equal match to double the grant amount depending on project category. Applicants must align with one of the priority sectors named in the UK's Modern Industrial Strategy ("Invest 2035"): advanced manufacturing, clean energy, digital and technologies, defence, creative industries, life sciences, or the Battery Innovation Programme. The competition closes 3 February 2026.
The UK Department of Health and Social Care, delivered via Innovate UK, awarded more than GBP 54 million in government funding across eight R&D projects on 18 November 2025 through the Sustainable Medicines Manufacturing Innovation Programme, matched by more than GBP 20 million from industry (combined GBP 74m+). The programme is funded through the GBP 400 million VPAG Investment Programme, agreed under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), and supports the manufacturing pillar of the UK's Modern Industrial Strategy Life Sciences Sector Plan. Funded projects include anaesthetic gas recovery/recycling (targeting ~GBP 5m annual NHS savings), converting spent nuclear fuel into radionuclide cancer therapies, CAR-T cell manufacturing scale-up (Royal Free Hospital), engineered bacteriophages for antibiotic resistance, and an AstraZeneca-led "Sustainable Future Factory" AI/robotics initiative.
The UK's state-owned National Wealth Fund (NWF) and UK Export Finance (UKEF), both wholly government-owned, jointly provided financial guarantees covering £272 million each (80% coverage of a £340 million loan facility) to unlock £680 million in commercial-bank financing for AESC's second battery gigafactory ("Plant 2") in Sunderland. The UK's Automotive Transformation Fund separately contributed £150 million in grants. Total investment mobilised exceeds £1 billion. The plant will add 15.8GWh of annual battery-cell capacity, supporting production of up to 100,000 electric vehicles per year and creating over 1,000 direct jobs in North East England.